Learn more about our upcoming Galas and Signature Events Learn More
DENVER, CO – The Melanoma Research Foundation (MRF) will host its 14th Annual Denver Gala on Thursday, September 18 at its new venue, Asterisk Denver. This year’s event...
Washington, DC (May 6, 2022) – The Melanoma Research Foundation (MRF) is thrilled to announce its annual Miles for Melanoma nationwide 5K program bringing together lo...
Guest blog from Leah Alexis Adams, a melanoma survivor whose anxiety from her 2019 diagnosis taught her the importance of sharing her story to bring awareness: I always t...
May 4 – The Melanoma Research Foundation (MRF) is proud to partner with Castle Biosciences during Melanoma Awareness Month to promote melanoma research, education and...
The Melanoma Research Foundation’s Annual Awareness Campaign Encourages Regular Skin Checks for Early Detection WASHINGTON, DC (May 2, 2022) – The Melanoma Research Fou...
Guest blog post by Summer Sanders, Olympic gold medalist in swimming, American sports commentator, reporter, television personality, actress, cutaneous melanoma survivor an...
Guest blog post by Monique Mack, “In the Sun” documentary participant, melanoma survivor and MRF advocate: My name is Monique Mack, and I am honored to be a...
ESTERO, FL (April 21, 2022) – The Melanoma Research Foundation (MRF) is thrilled to announce the start of its annual Miles for Melanoma nationwide 5K program bringing...
The MRF is proud to join our fellow members of the National Council on Skin Cancer Prevention (NCSCP) in urging the U.S. Food and Drug Administration (FDA) to finalize prop...
Guest blog post by Jamie Goldfarb, stage 4 melanoma survivor, clinical trial participant and melanoma advocate: I was diagnosed with stage 4 melanoma in January 2011. It...
Guest blog post by Katie Doble, ocular melanoma (OM) survivor, MRF Courage Award recipient and OM advocate: TIL therapy has given my family and me next-level hope. At 31 ye...
The Melanoma Research Foundation (MRF) is pleased to share recent significant achievements for the melanoma community. In March 2022, the U.S. Food and Drug Administration ...
On March 15, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Application (IND) for IOV-4001, its first geneti...
Sep 25, 2025 ET
